Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $7.73 million
- Book Value:
- Revenue TTM:
- $28.83 million
- Operating Margin TTM:
- Gross Profit TTM:
- $9.06 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Exicure Inc had its IPO on 2018-05-22 under the ticker symbol XCUR.
The company operates in the Healthcare sector and Biotechnology industry. Exicure Inc has a staff strength of 13 employees.
Shares of Exicure Inc opened at $0.84 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $0.84 - $0.9, and closed at $0.9.
This is a +2.62% increase from the previous day's closing price.
A total volume of 8,900 shares were traded at the close of the day’s session.
In the last one week, shares of Exicure Inc have increased by +4.65%.
Exicure Inc's Key Ratios
Exicure Inc has a market cap of $7.73 million, indicating a price to book ratio of 4.8516 and a price to sales ratio of 0.4223.
In the last 12-months Exicure Inc’s revenue was $28.83 million with a gross profit of $9.06 million and an EBITDA of $-668000. The EBITDA ratio measures Exicure Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Exicure Inc’s operating margin was -6.35% while its return on assets stood at -2.6% with a return of equity of -19.74%.
In Q4, Exicure Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 928%.
Exicure Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Exicure Inc’s profitability.
Exicure Inc stock is trading at a EV to sales ratio of 21.9714 and a EV to EBITDA ratio of 0.1259. Its price to sales ratio in the trailing 12-months stood at 0.4223.
Exicure Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $23.33 million
- Total Liabilities
- $1.64 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Exicure Inc ended 2023 with $23.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $23.33 million while shareholder equity stood at $14.92 million.
Exicure Inc ended 2023 with $0 in deferred long-term liabilities, $1.64 million in other current liabilities, in common stock, $-172649000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.58 million and cash and short-term investments were $8.58 million. The company’s total short-term debt was $539,000 while long-term debt stood at $0.
Exicure Inc’s total current assets stands at $10.05 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $361000.00 and inventory worth $0.
In 2023, Exicure Inc's operating cash flow was $0 while its capital expenditure stood at $10000.
Comparatively, Exicure Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Exicure Inc stock is currently trading at $0.9 per share. It touched a 52-week high of $4.95 and a 52-week low of $4.95. Analysts tracking the stock have a 12-month average target price of $5.5625.
Its 50-day moving average was $0.97 and 200-day moving average was $1.27 The short ratio stood at 8.07 indicating a short percent outstanding of 0%.
Around 5697% of the company’s stock are held by insiders while 1246.6% are held by institutions.
Frequently Asked Questions About Exicure Inc
Similar Industry Stocks (Biotechnology)
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company’s preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.